Skip to Main Content
Back to News

West Pharmaceutical Services Stock (WST) Opinions on Q2 Earnings Beat

None

Recent discussions on X about West Pharmaceutical Services (WST) have centered around the company’s latest earnings report, which exceeded expectations for both sales and earnings. Posts on the platform highlight the company’s raised full-year guidance, with some users noting the strong growth driven by demand for injectable drug delivery systems, particularly in the GLP-1 category. The stock’s significant surge post-earnings, even retaking key technical levels, has sparked lively engagement among investors.

However, not all reactions on X are uniformly positive, as some posts point to a sharp drop in stock price despite the earnings beat, with a few describing the market reaction as an overreaction. There’s a mix of optimism about the company’s fundamentals and caution regarding potential headwinds like destocking and operational challenges mentioned in analyst reports. This dynamic has kept the conversation intense and multifaceted across the platform.

Note: This discussion summary was generated from an AI condensation of post data.

West Pharmaceutical Services Congressional Stock Trading

Members of Congress have traded $WST stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $WST stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

West Pharmaceutical Services Hedge Fund Activity

We have seen 351 institutional investors add shares of West Pharmaceutical Services stock to their portfolio, and 367 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

West Pharmaceutical Services Analyst Ratings

Wall Street analysts have issued reports on $WST in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Evercore ISI Group issued a "Outperform" rating on 07/25/2025
  • UBS issued a "Buy" rating on 07/25/2025
  • Keybanc issued a "Overweight" rating on 02/14/2025

To track analyst ratings and price targets for West Pharmaceutical Services, check out Quiver Quantitative's $WST forecast page.

West Pharmaceutical Services Price Targets

Multiple analysts have issued price targets for $WST recently. We have seen 4 analysts offer price targets for $WST in the last 6 months, with a median target of $322.5.

Here are some recent targets:

  • Daniel Markowitz from Evercore ISI Group set a target price of $350.0 on 07/25/2025
  • John Sourbeer from UBS set a target price of $320.0 on 07/25/2025
  • Luke Sergott from Barclays set a target price of $245.0 on 06/24/2025
  • Paul Knight from Keybanc set a target price of $325.0 on 02/14/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Add Quiver Quantitative to your Google News feed.Google News Logo

Suggested Articles